For the new guys, something to keep in mind with this product is that it is a medical device, not a drug. So the regulatory hurdles are much smaller, my impression is that they are all but cleared for the first protein formula, but they need to do another small test with the new single protein formula.
By the end of the year we should have a commercial agreement, and they are looking at revenue next year. Its a much better story than some of the other biotechs that ran these past week.
TIS Price at posting:
22.0¢ Sentiment: ST Buy Disclosure: Held